Frontlight ResearchEarly access
Taking people in DenmarkPhase 2/3
Melatonin or low-dose quetiapine for sleep problems in teenagers with psychiatric disorders
Compares melatonin, low-dose quetiapine and placebo for insomnia in adolescents with psychiatric disorders.
Key facts
- Who runs it
- Region Hovedstaden
- Where
- Copenhagen Nv, DenmarkSee the site
- Trial code
- Registry title
- Melatonin versus quetiapine in adolescents (MEL-QUE-A)
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 255 people, planned
- Started
- 18 Aug 2025
- Expected to end
- 28 Feb 2029
- Type of study
- Interventional
- Record updated
- 11 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adolescents aged 16 to 17 with a mental or behavioral disorder who also have insomnia (trouble sleeping). It compares melatonin, low-dose quetiapine and placebo (a dummy pill).
- Age
- 16 to 17 years
- Sex
- All sexes can join
- Disease stage
- A current or previous mental or behavioral disorder (ICD-10 F20-F69, F84, F90-F95). Sleep problems at least three times per week in the past 3 months. Insomnia Severity Index score ≥11.
- Earlier treatment
- Non-drug options such as sleep hygiene education, a weighted blanket or other gravity products must have been tried without enough effect. People with F84 or F90 diagnoses must have had melatonin treatment before. People currently taking melatonin or quetiapine cannot join.
Main reasons for not taking part
- Current treatment with melatonin or quetiapine
- Severe other physical illness
- BMI ≥ 35 kg/m2
- Breastfeeding, or alcohol or drug dependency in the last 3 months
- Higher heart risk, including a prolonged QT-interval on the ECG (heart tracing)
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- 16 to 17 years of age
- ICD-10 diagnosis of a current or previous mental or behavioral disorder (F20-F69, F84, F90-F95)
- For the diagnoses F84 and F90 a previous period of treatment with melatonin is required
- Self-reported sleep difficulties at least three times per week in the preceding 3 months
- Insomnia Severity Index score ≥11
- Non-pharmacological treatment options including sleep hygiene education, weighted blanket or other gravity products have been tested with insufficient effect
- Women of childbearing potential: negative pregnancy test at baseline and use of highly effective contraception measures
- Informed consent provided by both the minor and the legally designated representative
Who cannot take part
- Current treatment with melatonin or quetiapine
- Increased cardiac risk as assessed by presence of cardiac risk factors, cardiac symptoms, or prolonged QT-interval at baseline electrocardiogram (ECG)
- Severe somatic comorbidity
- BMI ≥ 35 kg/m2
- Breastfeeding
- Alcohol and/or substance dependency (F1X.2) within the last 3 months
- Inadequate Danish language skills
- Not able to make an informed consent
Where in Denmark
- Psykiatrisk Center KobenhavnCopenhagen Nv, DenmarkTaking people
About the trial
What the trial wants to find out
To examine the efficacy of melatonin or low-dose quetiapine versus placebo for treatment of insomnia.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Efficacy of melatonin, low-dose quetiapine, or placebo in adolescents with psychiatric disorders and comorbid insomnia: a randomized clinical trial
- Plain-language title
- Melatonin or low-dose quetiapine for sleep problems in teenagers with psychiatric disordersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 11 November 2026